Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will Wave Life Sciences keep quarterly R&D expenses below $60M for all quarters of FY2026?
Current Prediction
Why This Question Matters
R&D spend above $60M/quarter was flagged as a CRITICAL monitoring threshold by the Stress Scanner. Staying below $60M suggests disciplined pipeline management. Exceeding it would compress the cash runway below Q3 2028 guidance, potentially forcing a dilutive financing at an inopportune time.
Prediction Distribution
Individual Predictions(9 runs)
Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Management guided Q3 2028 runway implying burn discipline provides partial support, but q4 2025 already at $52.8m trending up ~$2-3m/quarter creates counterweight. Probability: 0.25.
Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Management guided Q3 2028 runway implying burn discipline provides partial support, but q4 2025 already at $52.8m trending up ~$2-3m/quarter creates counterweight. Probability: 0.47.
Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Management guided Q3 2028 runway implying burn discipline provides partial support, but q4 2025 already at $52.8m trending up ~$2-3m/quarter creates counterweight. Probability: 0.46.
Base rate evidence: q4 2025 already at $52.8m trending up ~$2-3m/quarter. Partial offset from management guided q3 2028 runway implying burn discipline. Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Probability: 0.35.
Base rate evidence: q4 2025 already at $52.8m trending up ~$2-3m/quarter. Partial offset from management guided q3 2028 runway implying burn discipline. Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Probability: 0.35.
Base rate evidence: q4 2025 already at $52.8m trending up ~$2-3m/quarter. Partial offset from management guided q3 2028 runway implying burn discipline. Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Probability: 0.39.
Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Balance of evidence suggests 0.5 probability. Primary support: management guided q3 2028 runway implying burn discipline. Main counterargument: q4 2025 already at $52.8m trending up ~$2-3m/quarter.
Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Balance of evidence suggests 0.31 probability. Primary support: management guided q3 2028 runway implying burn discipline. Main counterargument: q4 2025 already at $52.8m trending up ~$2-3m/quarter.
Natural trajectory approaches $60M by Q3-Q4 2026 - all 4 quarters below requires active burn management. Balance of evidence suggests 0.35 probability. Primary support: management guided q3 2028 runway implying burn discipline. Main counterargument: q4 2025 already at $52.8m trending up ~$2-3m/quarter.
Resolution Criteria
Resolves YES if Wave reports quarterly R&D expenses below $60M for all four quarters of FY2026. Resolves NO if any quarter exceeds $60M.
Resolution Source
Wave Life Sciences quarterly 10-Q and annual 10-K filings
Source Trigger
R&D expenses at $52.8M (Q4 2025) and rising; exceeding $60M/quarter would compress runway below Q3 2028 guidance
Full multi-lens equity analysis